primaquine phosphate

CLINICAL USE

Treatment of malaria ( Plasmodium vivax and Plasmodium ovale), in combination with chloroquineTreatment of Pneumocystis jiroveci pneumonia (PCP), in combination with clindamycin

DOSE IN NORMAL RENAL FUNCTION

Malaria: 15–30 mg once daily for 14 days PCP: 30 mg once daily

PHARMACOKINETICS

Molecular weight :455.3

%Protein binding :No data

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :3–4

half-life – normal/ESRD (hrs) :3–6/Unknown

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antimalarials: avoid concomitant use with artemether/lumefantrine

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Primaquine base 7.5 mg is approximately equivalent to 13.2 mg primaquine phosphateMajor metabolite, 8-(3-carboxyl-1- methylpropylamino)-6-methoxyquinolone, possesses less antimalarial activity than the parent compound

Contraindicated in acutely ill patients with rheumatoid arthritis or SLE – increased risk of developing granulocytopeniaRisk of haemolytic anaemia in patients with G-6-PD deficiency; haemolysis generally appears 2–3 days after primaquine administration. Risk of methaemoglobinaemia at high doses

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home